Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Adaptimmune Therapeutics (ADAP) today and set a price target of $9.00. The company’s shares closed last Thursday at $4.66.
According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 11.1% and a 42.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Corvus Pharmaceuticals, and Neoleukin Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adaptimmune Therapeutics with a $10.00 average price target, a 109.6% upside from current levels. In a report issued on November 5, Leerink Partners also maintained a Hold rating on the stock with a $6.00 price target.
See today’s analyst top recommended stocks >>
Based on Adaptimmune Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.19 million and GAAP net loss of $35.43 million. In comparison, last year the company earned revenue of $237K and had a GAAP net loss of $39.3 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
